Respiratory Syncytial Virus Diagnostics Market Top Players, Segments & Regional Trends By 2034

Straits Research released its highly anticipated report, “Global Respiratory Syncytial Virus Diagnostics Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 6.65 billion in 2025 and is projected to expand to USD 10.89 billion by 2034, registering a compound annual growth rate (CAGR) of 5.68%.

Market Dynamics

The global respiratory syncytial virus diagnostics market is witnessing steady expansion due to the rising global burden of RSV infections among infants, older adults, and immunocompromised individuals, which has heightened the need for early and accurate detection. Increasing adoption of rapid molecular diagnostic technologies, such as point-of-care PCR assays, is further accelerating market growth by enabling clinicians to identify RSV quickly and improve case management during peak seasonal outbreaks. Additionally, growing integration of multiplex respiratory panels in hospitals and diagnostic centers supports efficient differentiation between RSV, influenza, and other viral pathogens, enhancing clinical decision-making and reducing unnecessary treatments.

However, the market continues to face restraints related to the high cost of advanced RSV molecular testing systems and the operational expenses associated with maintaining laboratory infrastructure. In many low-income regions, limited reimbursement coverage and insufficient diagnostic capacity hinder widespread adoption of innovative RSV testing solutions. Despite these challenges, key opportunities are emerging as RSV gains global attention due to the recent introduction of preventive vaccines and monoclonal antibodies, which are expected to increase screening volumes. Expansion of decentralized testing through affordable rapid antigen and molecular point-of-care devices offers strong growth potential in community settings and outpatient clinics.

Key Highlights

• Product: The kits & assays segment dominated the market with a revenue share of 46.56% in 2025.
• Method: The molecular diagnostics segment is estimated to grow at the fastest pace with a CAGR of 6.28%.
• End User: The hospitals & clinics segment dominated the market in 2025 with a revenue share of 43.07%, owing to the high volume of patients seeking respiratory care during seasonal RSV.
• Regional Insights: North America accounted for 41.19% market share in 2025, driven by high awareness of respiratory infections and widespread adoption of advanced molecular diagnostics.